The Degree Of Intravesical Prostatic Protrusion Can Predict The Treatment Response For Male Overactive Bladder Patients Treated With Mirabegron
Dr Yuan-chi Shen (1), Prof Yao-Chi Chuang (1), Associate Prof Wei-Chia Lee (1), Dr Hung Jen Wang (1)
(1) Kaohsiung Chang Gung Memorial hospital, Kaohsiung, Taiwan
Overactive bladder (OAB) is a concomitant condition associated with BPO and intravesical prostatic protrusion (IPP) is a morphometric parameter associated with the degree of benign prostatic obstruction (BPO). Mirabegron, a selective 3 adrenoceptor agonist, is widely used for treatment of OAB. We aimed to evaluate the treatment response in male OAB patients with different degree of IPP.
We enrolled a consecutive cohort of 192 male LUTS patients ≥ 40 years in a tertiary referral center. The patients with OABSS urgency score of ≥2 and sum score of ≥3 was defined as the OAB group and treated with Mirabegron 50mg. The therapeutic outcomes were assessed at baseline, 4, and 12 weeks in three different degree of IPP groups (0-5mm, 6-10 mm and more than 10mm).
Mirabegron usage was associated with a statistically significant decrease in OABSS total score at 4-week (8.1 ± 2.5 to 6.2 ±2.7, p = 0.0036) and a further 10% decrease at 12-week in IPP 0-5mm group but insignificant in groups of IPP 6-10mm and >10mm. The sub-score of urgency, urge incontinence and nocturia was also significant decreased at 4-week in IPP 0-5mm group and insignificant in other two groups.
The degree of IPP ≦5mm can predict the satisfactory treatment response with Mirabegron 50mg in reducing OAB symptom, especially urgency, urge incontinence and nocturia for male patient.